Minimal residual disease (MRD)—minute populations of cancer cells undetectable by conventional imaging—remains the chief ...

Axi-cel demonstrated a 90% overall response rate and 75% complete response rate in relapsed/refractory indolent non-Hodgkin lymphoma. Median progression-free survival was 62.2 months, with a median ...

Ike Onwere, MD: It is [sometimes] based on giving the FOLFOX [leucovorin, fluorouracil, and oxaliplatin] every 2 weeks. It’s ...

Biomarkers such as ring sideroblasts are indicators for response to treatments like luspatercept (Reblozyl). In patients with ...

While this panel has grown in recent years, many experts believe additional biomarkers should also be incorporated as ...

The FDA has approved durvalumab (Imfinzi) plus fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for the treatment ...

FDA approves daratumumab for high-risk smoldering multiple myeloma, transforming treatment strategies and enhancing patient outcomes in early intervention.

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and ...

Sonrotoclax has received FDA priority review for relapsed or refractory mantle cell lymphoma, indicating potential substantial treatment improvement. The BGB-11417-201 study demonstrated significant ...

Benjamin George, MD, has significantly improved cancer care access in rural Nebraska, Colorado, and Kansas, transforming ...

RP1 and nivolumab combination achieved a 32.9% objective response rate and 15.0% complete response rate in advanced melanoma ...

A phase 2 study reveals high efficacy and manageable safety of venetoclax plus obinutuzumab for untreated CLL/SLL in Japanese ...